神經病學領域臨床試驗市場規模、佔有率和成長分析：按階段、研究設計、適應症、申辦者和地區分類－2026-2033年產業預測

2024 年全球神經系統臨床試驗市場價值為 52.2 億美元，預計到 2025 年將成長至 55.5 億美元，到 2033 年將成長至 91.1 億美元，在預測期（2026-2033 年）內複合年成長率為 6.39%。

全球神經系統疾病臨床試驗市場是一個充滿活力的研發領域，致力於開發針對中樞和周邊神經系統疾病的治療方法、診斷方法和醫療設備。這一市場的發展主要受阿茲海默症和帕金森氏症等神經退化性疾病日益普遍的推動。標靶澱粉樣蛋白藥物的問世顯著促進了臨床試驗的開展，而包括「突破性療法」認定在內的監管激勵措施也加速了受試者的招募和資金籌措。目前，眾多贊助商、新創公司和聯盟正湧入該市場，以期從這個不斷擴展的治療領域中獲益。此外，生物標記的引入和創新試驗設計的出現提高了受試者招募和數據收集的效率，而穿戴式感測器和行動應用程式則實現了對疾病進展的即時追蹤。在監管支持下，這一成長趨勢正為個人化醫療和臨床試驗網路的進一步發展奠定基礎。

全球神經系統臨床試驗市場的促進因素

阿茲海默症、帕金森氏症、多發性硬化症和癲癇等神經系統疾病的日益普遍，推動了對創新療法的需求，進而促進了臨床試驗的增加。隨著患者數量的成長，入組變得更加容易，這反過來又刺激了對研究基礎設施的投資，並促進了學術機構、合約研究組織（CRO）和製藥公司之間的夥伴關係。這種合作氛圍強化了開發平臺，並推動了全球神經系統疾病臨床試驗市場的持續成長。此外，跨區域的多中心合作研究正在加深我們對疾病進展機制的科學理解，並提高對監管規定的適應能力。

全球神經系統臨床試驗市場的限制因素

全球神經病學臨床試驗市場面臨嚴峻挑戰，這主要是由於旨在確保神經系統疾病治療安全性和有效性的嚴格監管要求。這些標準要求提供大量的臨床前數據、較長的追蹤期以及全面的終點檢驗，這使得試驗設計複雜化並延長了審查週期。因此，申辦方被迫投入更多資源並採取更保守的研發策略。這種情況不僅延緩了新試驗的啟動，阻礙了市場成長，也打擊了那些可能難以滿足這些嚴格合規標準的中小型企業的積極性。最終，試驗營運往往集中在大規模跨國公司手中，進一步限制了市場競爭。

全球神經系統臨床試驗市場趨勢

全球神經病學臨床試驗市場正經歷一場變革，而神經藥理學領域的創新正是推動這項變革的動力。基因編輯療法、生物製藥和精準醫療的融合正在重塑臨床調查方法，申辦方紛紛採用適應性方案，以期儘早獲得洞見並擴大基於生物標記的隊列。這一演變加強了生物技術公司與學術機構之間的合作，提高了獲得先進平台和針對罕見神經系統疾病特定患者群體的機會。因此，市場正朝著更靈活、以科學為導向的方向發展，優先考慮標靶策略而非傳統的廣泛招募受試者，同時也改善國際市場的監管環境，最終提高試驗的成功率。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球神經學領域臨床試驗市場規模：依階段分類

• 第一階段
• 第二階段
• 第三階段
• 第四階段（上市後）

全球神經學領域臨床試驗市場規模：依研究設計分類

• 干預研究
• 觀察性研究

全球神經學領域臨床試驗市場規模：依適應症分類

• 阿茲海默症
• 帕金森氏症
• 多發性硬化症
• 癲癇
• 肌萎縮側索硬化症（ALS）
• 中風
• 其他中樞神經系統疾病

全球神經病學領域臨床試驗市場規模：依申辦方分類。

• 製藥和生物技術公司
• 大學和研究機構
• 政府機構

全球神經病學領域臨床試驗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• IQVIA Holdings Inc.
• Covance（Labcorp Drug Development）
• Charles River Laboratories
• Medpace Holdings
• Syneos Health
• Icon plc
• PARENTEXEL International
• PPD（Thermo Fisher Scientific）
• Novatek International
• International SOS
• Biogen Inc.
• Novartis AG
• Eli Lilly and Company
• GlaxoSmithKline
• Roche Holding AG
• Johnson & Johnson（Janssen）
• AstraZeneca
• AbbVie Inc.
• Alector LLC
• Denali Therapeutics Inc.

結論與建議

Global Neurology Clinical Trials Market size was valued at USD 5.22 Billion in 2024 and is poised to grow from USD 5.55 Billion in 2025 to USD 9.11 Billion by 2033, growing at a CAGR of 6.39% during the forecast period (2026-2033).

The global neurology clinical trials market represents a dynamic arena for investigating therapeutics, diagnostics, and devices targeting central and peripheral nervous system disorders, driven by rising incidences of neurodegenerative diseases such as Alzheimer's and Parkinson's. The introduction of amyloid-targeting agents significantly stimulated trial activity, while regulatory incentives, including Breakthrough Therapy designations, facilitated faster enrollment and funding. An influx of sponsors, startups, and consortia now seek to capitalize on this expanding therapeutic landscape. Additionally, the integration of biomarkers and innovative trial designs enhances recruitment efficiency and data collection, with wearable sensors and mobile applications enabling real-time tracking of disease progression. This growth trajectory, supported by regulatory endorsements, positions the market for further advancements in personalized therapeutics and trial networks.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurology Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurology Clinical Trials Market Segments Analysis

Global neurology clinical trials market is segmented by phase, study design, indication, sponsor and region. Based on phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV (Post-Marketing). Based on study design, the market is segmented into Interventional Studies and Observational Studies. Based on indication, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, ALS (Amyotrophic Lateral Sclerosis), Stroke and Other CNS Disorders. Based on sponsor, the market is segmented into Pharmaceutical & Biotech Companies, Academia & Research Institutes and Government Agencies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurology Clinical Trials Market

The rising prevalence of neurological disorders like Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is fueling the demand for innovative treatment options, leading to an increase in clinical trials. As the patient population grows, enrolling participants becomes easier, which in turn promotes investment in research infrastructure and fosters partnerships among academic institutions, contract research organizations, and pharmaceutical companies. This collaborative atmosphere enhances the development pipeline, driving sustained growth in the global neurology clinical trials market. Additionally, it deepens the scientific understanding of disease processes and encourages regulatory adaptability through multi-center collaborations across various regions.

Restraints in the Global Neurology Clinical Trials Market

The Global Neurology Clinical Trials market faces significant challenges due to stringent regulatory requirements aimed at ensuring safety and efficacy in neurological therapies. These standards necessitate extensive pre-clinical data, prolonged follow-up periods, and thorough validation of endpoints, which complicate trial designs and extend review periods. As a result, sponsors are compelled to dedicate more resources and adopt more conservative development approaches. This situation leads to a slowdown in the initiation of new trials, hindering market growth and discouraging smaller companies that may struggle to meet these heightened compliance standards. Consequently, trial operations often consolidate within larger multinational firms, further restricting competition.

Market Trends of the Global Neurology Clinical Trials Market

The Global Neurology Clinical Trials market is undergoing a transformative shift propelled by neuropharmaceutical innovation. The integration of gene-editing therapies, biologics, and precision medicine is redefining trial methodologies, with sponsors embracing adaptive protocols for early insights and biomarker-driven cohort expansions. This evolution is fostering increased collaboration between biotech firms and academic institutions, enhancing access to advanced platforms and niche patient populations with rare neurological conditions. As a result, the market is evolving into a more agile, science-oriented landscape, prioritizing targeted approaches over traditional broad enrollment, while also improving regulatory alignment across international markets, ultimately increasing the likelihood of successful outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neurology Clinical Trials Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III
• Phase IV (Post-Marketing)

Global Neurology Clinical Trials Market Size by Study Design & CAGR (2026-2033)

• Market Overview
• Interventional Studies
• Observational Studies

Global Neurology Clinical Trials Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Epilepsy
• ALS (Amyotrophic Lateral Sclerosis)
• Stroke
• Other CNS Disorders

Global Neurology Clinical Trials Market Size by Sponsor & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotech Companies
• Academia & Research Institutes
• Government Agencies

Global Neurology Clinical Trials Market Size & CAGR (2026-2033)

• North America (Phase, Study Design, Indication, Sponsor)
  • US
  • Canada
• Europe (Phase, Study Design, Indication, Sponsor)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Phase, Study Design, Indication, Sponsor)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Phase, Study Design, Indication, Sponsor)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Phase, Study Design, Indication, Sponsor)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• IQVIA Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance (Labcorp Drug Development)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Icon plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PARENTEXEL International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (Thermo Fisher Scientific)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novatek International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International SOS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Denali Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations